Abstract
Purpose
To detect early response to sunitinib treatment in metastatic clear cell renal cancer (mRCC) using multiparametric MRI.
Method
Participants with mRCC undergoing pre-surgical sunitinib therapy in the prospective NeoSun clinical trial (EudraCtNo: 2005-004502-82) were imaged before starting treatment, and after 12 days of sunitinib therapy using morphological MRI sequences, advanced diffusion-weighted imaging, measurements of R2* (related to hypoxia) and dynamic contrast-enhanced imaging. Following nephrectomy, participants continued treatment and were followed-up with contrast-enhanced CT. Changes in imaging parameters before and after sunitinib were assessed with the non-parametric Wilcoxon signed-rank test and the log-rank test was used to assess effects on survival.
Results
12 participants fulfilled the inclusion criteria. After 12 days, the solid and necrotic tumor volumes decreased by 28% and 17%, respectively (p = 0.04). However, tumor-volume reduction did not correlate with progression-free or overall survival (PFS/OS). Sunitinib therapy resulted in a reduction in median solid tumor diffusivity D from 1298x10-6 to 1200x10-6mm2/s (p = 0.03); a larger decrease was associated with a better RECIST response (p = 0.02) and longer PFS (p = 0.03) on the log-rank test. An increase in R2* from 19 to 28s-1 (p = 0.001) was observed, paralleled by a decrease in Ktrans from 0.415 to 0.305min-1 (p = 0.01) and a decrease in perfusion fraction from 0.34 to 0.19 (p<0.001).
Conclusions
Physiological imaging confirmed efficacy of the anti-angiogenic agent 12 days after initiating therapy and demonstrated response to treatment. The change in diffusivity shortly after starting pre-surgical sunitinib correlated to PFS in mRCC undergoing nephrectomy, however, no parameter predicted OS.
Trial registration
EudraCtNo: 2005-004502-82.
Funder
Cancer Research UK
Cancer Research UK Cambridge Centre
Cambridge Commonwealth, European and International Trust
Mark Foundation For Cancer Research
Engineering and Physical Sciences Research Council Cancer Imaging Centre in Cambridge and Manchester
NIHR Cambridge Biomedical Research Centre
Cambridge Experimental Cancer Medicine Centre
Cambridge Clinical Trials Unit
Addenbrooke’s Charitable Trust
Publisher
Public Library of Science (PLoS)
Reference35 articles.
1. Kidney and Renal Pelvis Cancer; Stage Distribution of SEER Incidence Cases, 2005–2014 2014.
2. Stage Breakdown bc CCG 2014 2016.
3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;B Escudier;Ann Oncol,2019
4. eUpdate–Renal Cell Carcinoma Treatment Recommendations;T Powles;ESMO,2020
5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1);EA Eisenhauer;Eur J Cancer,2009
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献